Coronavirus: AstraZeneca’s US trial questioned; Germany reverses reopening plans

Results from a US trial of AstraZeneca’s Covid-19 vaccine may have included “outdated information” and that could mean the company provided an incomplete view of efficacy data, American federal health officials said early on Tuesday. AstraZeneca said in a statement that the data it released on Monday included cases up to February 17, as the study rules specified, and that it was continuing to analyse cases that have occurred since then. The company said that a preliminary analysis of data that…

Read the original article at South China Morning Post